Literature DB >> 21997225

Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.

J Compston1.   

Abstract

In recent years, atypical femoral fractures and osteonecrosis of the jaw have emerged as potential complications of long-term bisphosphonate therapy; osteonecrosis of the jaw has also been reported in patients receiving high doses of denosumab. The pathophysiology of both conditions is poorly defined, and the underlying mechanisms are likely to differ. The initiation of atypical fractures in the lateral femoral shaft suggests that reduced tensile strength, possibly secondary to alterations in the material properties of bone resulting from low bone turnover, may be an important pathogenetic factor. Osteonecrosis of the jaw is characterised by infection, inflammation, bone resorption and bone necrosis, but the sequence in which these occur has not been established. However, the observation that bone resorption occurs in close proximity to microbial structures suggests that infection may be the most important trigger, often as a result of dental disease. Other possible pathogenetic factors include suppression of bone turnover, altered immune status and adverse effects of bisphosphonates on the oral mucosa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997225     DOI: 10.1007/s00198-011-1804-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  89 in total

Review 1.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

2.  Effects of non-enzymatic glycation on cancellous bone fragility.

Authors:  S Y Tang; U Zeenath; D Vashishth
Journal:  Bone       Date:  2006-12-21       Impact factor: 4.398

3.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

Review 4.  Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Authors:  S Ferrari-Lacraz; S Ferrari
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

5.  In vivo effects of zoledronic acid on oral mucosal epithelial cells.

Authors:  E Allam; Mr Allen; T-M Chu; A Ghoneima; L Jack Windsor
Journal:  Oral Dis       Date:  2010-09-23       Impact factor: 3.511

6.  Atypical bilateral pedicle fracture in long-term bisphosphonate therapy.

Authors:  Rami El Rachkidi; Marie-Laure Sari-Leret; Stephane Wolff
Journal:  Spine (Phila Pa 1976)       Date:  2011-12-15       Impact factor: 3.468

7.  Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

Authors:  Torsten Hansen; Martin Kunkel; Achim Weber; C James Kirkpatrick
Journal:  J Oral Pathol Med       Date:  2006-03       Impact factor: 4.253

8.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

9.  Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.

Authors:  Felice S O'Ryan; Sam Khoury; Wendy Liao; Myo M Han; Rita L Hui; David Baer; Daniel Martin; Donald Liberty; Joan C Lo
Journal:  J Oral Maxillofac Surg       Date:  2009-07       Impact factor: 1.895

10.  Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

Authors:  Matthew R Allen; David B Burr
Journal:  J Bone Miner Res       Date:  2007-11       Impact factor: 6.741

View more
  35 in total

1.  Diagnosis and management of bilateral diaphyseal femoral fracture.

Authors:  Antonia García-Martín; Rebeca Reyes-García; Mariela Varsavsky; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

2.  Comment on Compston: pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.

Authors:  K Michaëlsson; J Schilcher; P Aspenberg
Journal:  Osteoporos Int       Date:  2012-12       Impact factor: 4.507

3.  Osteonecrosis and atypical fractures-common origins?

Authors:  G Subramanian; J C Fritton; S Y P Quek
Journal:  Osteoporos Int       Date:  2012-03-10       Impact factor: 4.507

Review 4.  Atypical femoral fractures: epidemiology, etiology, and patient management.

Authors:  Eve Donnelly; Anas Saleh; Aasis Unnanuntana; Joseph M Lane
Journal:  Curr Opin Support Palliat Care       Date:  2012-09       Impact factor: 2.302

Review 5.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

Review 6.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

7.  Atypical femoral fractures: retrospective radiological study of 319 femoral fractures and presentation of clinical cases.

Authors:  V Bottai; S Giannotti; G Dell'osso; G De Paola; A Menconi; F Falossi; G Raffaetà; G Guido
Journal:  Osteoporos Int       Date:  2013-10-31       Impact factor: 4.507

8.  Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.

Authors:  Yoichi Iizuka; Rumi Takechi; Haku Iizuka; Takuya Omodaka; Kenji Takagishi
Journal:  Skeletal Radiol       Date:  2016-07-11       Impact factor: 2.199

Review 9.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

Review 10.  Osteoporosis in men: recent progress.

Authors:  Robert A Adler
Journal:  Endocrine       Date:  2013-01-25       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.